Cellon debuts sterile single-use containers

Published: 27-Apr-2012
Pharmaceutical

The range is ideal for use in the handling and storage of biologicals

A new range of sterile single-use containers for storage, freezing, and manipulation of biological solutions has been launched by Luxembourg-based Cellon SA, a provider of products and services for vaccine production and bioprocessing.

Called PharmaTainer, the line of products are a range of low particulate, single use bottles and carboys for the storage/transport of bulk vaccines, biopharmaceuticals, culture media and other biotech materials.

The plastic containers are injection blow moulded in an ISO Class 5 (Class100) environment and radiation sterilised. These rigid ultra-clean containers are available in sizes from 125ml to 20L. They are manufactured from resins approved for medical applications in PET or polycarbonate with HDPE closures.

PharmaTainer packaging features three inner layers of poly wrapping to facilitate delivery into cleanroom areas. The inner most layer is vacuum-sealed providing tamper evidence and assurance of an intact sterility barrier.

The range of products feature traceability down to the individual container. Each bottle/carboy is printed with a unique serial number, batch number, expiration date and a machine-readable data matrix. The machine-readable serial number can be readily integrated with the user’s inventory management system.

All PharmaTainer products are produced in a new, moulding facility, dedicated solely to production of sterile, single-use products for biotechnology industries.

European customers may get further information at www.cellon.lu or by email sales@cellon.lu. The products are distributed by Biofluid Focus in North American (www.biofluidfocus.com).




See more

You may also like

Manufacturing

3i builds single-use bioprocessing platform using three acquisitions

Read more
The UK-based company has acquired Cellon, Silicone Altimex and TBL Performance Plastics to establish a platform serving the high growth single-use technology market

Trending Articles

  1. FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
  2. FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
  3. Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026 Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
  4. Indena to highlight expanded HPAPI, ADC and peptide drug conjugate capabilities at DCAT Week 2026 Italian CDMO Indena will showcase its high-potency API manufacturing expertise and growing oncology-focused capabilities at DCAT Week in New York, including ten commercial HPAPIs in production and advancing work in antibody-drug and peptide drug conjugates
  5. dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

3i builds single-use bioprocessing platform using three acquisitions

The UK-based company has acquired Cellon, Silicone Altimex and TBL Performance Plastics to establish a platform serving the high growth single-use technology market
Regulatory

FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Pharmaceutical

Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026

Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
Regulatory

FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths

The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
Manufacturing

Bio-Sourcing and Tiny Cargo collaborate to develop oral monoclonal antibody therapies

Bio-Sourcing and Tiny Cargo Company have announced a strategic alliance to co-develop oral monoclonal antibody therapies using goat milk extracellular vesicles
Regulatory

NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer

MSD's KEYTRUDA (pembrolizumab) has received NICE approval as a neoadjuvant and adjuvant therapy for resectable LA HNSCC—the first immunotherapy recommended in this perioperative setting and the first treatment advance in more than two decades
Finance

Merck to acquire cancer biotech Terns Pharmaceuticals for $6.7bn

The purchase is the third multibillion-dollar acquisition for the pharma giant in the past year, as it moves to bolster its cancer portfolio ahead of its best-selling drug Keytruda losing patent protection in 2028
Subscribe now